Key result
Polypill therapy reduces MACE by ~25% versus standard care.
Why the study?
Cardiovascular disease has a rising prevalence and mortality, making primary and secondary prevention strategies crucial, particularly in resource-scarce settings where polypills hold significant potential.
Does a polypill strategy reduce major adverse cardiovascular events and cardiovascular mortality compared to standard care or placebo in patients undergoing primary or secondary prevention?
Meta-Analysis (n=33,513)
Does a polypill strategy reduce major adverse cardiovascular events and cardiovascular mortality compared to standard care or placebo in patients undergoing primary or secondary prevention?
Effect estimate: RR 0.75 (95% CI 0.68-0.84)
p-value: p=0.004
A polypill strategy significantly reduces cardiovascular mortality, MACE, systolic blood pressure, and LDL-C compared to standard care or placebo in both primary and secondary prevention settings.
Supports polypill consideration in prevention; reinforces meta-analytic evidence for both primary and secondary settings.
A significant global health concern, cardiovascular disease (CVD) is characterized by a rising prevalence and accompanying mortality rates. It is crucial to implement primary and secondary prevention strategies, particularly in resource-scarce settings. Polypills, which combine blood pressure, cholesterol, and homocysteine drugs, hold significant potential for lowering the risk of CVD. This study follows PRISMA meta-analysis guidelines. Two researchers conducted an extensive literature search. Inclusion criteria encompassed RCT design, polypill use, a four-week duration, and one meta-analysis outcome. Primary outcomes included MACE and CV mortality, while secondary outcomes encompassed SBP and LDL-C changes. Data extraction was performed independently, and conflicts were resolved. Review Manager 5.4 with random effects was employed for statistical analysis, and ROB 2.0 bias evaluation was conducted. The study reported CVD mortality and MACE risk ratios (RRs) with 95% CIs, as well as SBP and LDL-C weighted mean differences (MD). A total of 24 trials were included in this meta-analysis. The results revealed that the polypill was associated with a decreased risk of CVD mortality and major adverse cardiovascular events (MACE). Additionally, a significant reduction in systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) was observed. This meta-analysis showed that polypill is a viable medication for reducing the risk of CVD mortality and MACE. It is also a beneficial medication for lowering LDL-C levels and SBP.
No takes yet. Share an insight, caveat, or question.
Virk et al. (2023) conducted a meta-analysis in Cardiovascular disease (n=33,513). Polypill vs. Standard care or placebo was evaluated on Major adverse cardiovascular events (MACE) (RR 0.75, 95% CI 0.68-0.84, p=0.004). Polypill therapy significantly reduced the risk of major adverse cardiovascular events (RR 0.75) and cardiovascular mortality (RR 0.73) compared to standard care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: